{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:27:52Z","timestamp":1786609672152,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"DOI":"10.1007\/s10096-026-05623-0","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:35:58Z","timestamp":1786606558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is early combination therapy associated with lower risk of respiratory failure in severely immunocompromised hosts with COVID-19? a target trial emulation study from the omicron-dominant era"],"prefix":"10.1007","author":[{"given":"Davide Fiore","family":"Bavaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Diella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Belati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Poliseno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Francesca","family":"Bottalico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Rosario Paolo","family":"Ieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"De Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Pallara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Muscatiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Buccoliero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lo Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Carbonara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"5623_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41577-022-00720-5","volume":"22","author":"A Sigal","year":"2022","unstructured":"Sigal A, Milo R, Jassat W (2022) Estimating disease severity of Omicron and Delta SARS-CoV-2 infections. Nat Rev Immunol 22:267\u2013269. https:\/\/doi.org\/10.1038\/s41577-022-00720-5","journal-title":"Nat Rev Immunol"},{"key":"5623_CR2","doi-asserted-by":"publisher","unstructured":"Evans RA, Dube S, Lu Y, Yates M, Arnetorp S, Barnes E, Bell S, Carty L, Evans K, Graham S, Justo N, Moss P, Venkatesan S, Yokota R, Ferreira C, McNulty R, Taylor S, Quint JK (2023) Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. Lancet Reg Health Eur. ;35:100747. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100747. Erratum in: Lancet Reg Health Eur. 2024;44:101008. doi: 10.1016\/j.lanepe.2024.101008. PMID: 38115964; PMCID: PMC10730312","DOI":"10.1016\/j.lanepe.2023.100747"},{"key":"5623_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1259","volume":"12","author":"J Bytyci","year":"2024","unstructured":"Bytyci J, Ying Y, Lee LYW (2024) Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: a systematic review. Immunity Inflamm Dis 12:e1259","journal-title":"Immunity Inflamm Dis"},{"key":"5623_CR4","doi-asserted-by":"publisher","first-page":"209e18","DOI":"10.1007\/s40472-022-00385-y","volume":"9","author":"V Dioverti","year":"2022","unstructured":"Dioverti V, Salto-Alejandre S, Haidar G (2022) Immunocompromised patients with protracted COVID-19: a review of long persisters. Curr Transpl Rep 9:209e18. https:\/\/doi.org\/10.1007\/s40472-022-00385-y","journal-title":"Curr Transpl Rep"},{"issue":"3","key":"5623_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s15010-023-02138-0","volume":"52","author":"V G\u00f6tz","year":"2024","unstructured":"G\u00f6tz V, Math\u00e9 P, Agarwal P, Hornuss D, Pfau S, Panning M, Prager E, Voll RE, Engelhardt M, Frye BC, Bamberg F, Fuchs J, M\u00fcller M, Wagner D, Rieg S (2024) Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era. Infection 52(3):923\u2013933. https:\/\/doi.org\/10.1007\/s15010-023-02138-0","journal-title":"Infection"},{"key":"5623_CR6","doi-asserted-by":"publisher","first-page":"E312","DOI":"10.1002\/ajh.26626","volume":"97","author":"O Blennow","year":"2022","unstructured":"Blennow O, Salmanton-Garc\u00eda J, Nowak P et al (2022) Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report. Am J Hematol 97:E312\u2013E317","journal-title":"Am J Hematol"},{"key":"5623_CR7","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/S2666-5247(23)00336-1","volume":"5","author":"Z Raglow","year":"2024","unstructured":"Raglow Z, Surie D, Chappell JD et al (2024) SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis. Lancet Microbe 5:e235\u2013e246","journal-title":"Lancet Microbe"},{"issue":"11","key":"5623_CR8","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s40121-024-01052-8","volume":"13","author":"KZH Lai","year":"2024","unstructured":"Lai KZH, Greenstein S, Govindasamy R, Paranilam J, Brown J, Kimball-Carroll S (2024) COVID-19 vaccination recommendations for immunocompromised patient populations: Delphi panel and consensus statement generation in the United States. Infect Dis Ther 13(11):2255\u20132283. https:\/\/doi.org\/10.1007\/s40121-024-01052-8","journal-title":"Infect Dis Ther"},{"issue":"6","key":"5623_CR9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s40620-024-01889-9","volume":"37","author":"S Simone","year":"2024","unstructured":"Simone S, Pronzo V, Pesce F, Bavaro DF, Infante B, Mercuri S, Schirinzi A, Panaro A, Conte E, Belati A, Troise D, Pontrelli P, Conserva F, Gallo P, Panico M, Spilotros M, Lucarelli G, Saracino A, Stallone G, Di Serio F, Ditonno P, Gesualdo L (2024) Safety and efficacy of tixagevimab\/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study. J Nephrol 37(6):1539\u20131550. https:\/\/doi.org\/10.1007\/s40620-024-01889-9","journal-title":"J Nephrol"},{"issue":"6","key":"5623_CR10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/QCO.0000000000001070","volume":"37","author":"C Sepulcri","year":"2024","unstructured":"Sepulcri C, Bartalucci C, Mikulska M (2024) Antiviral combination treatment strategies for SARS-CoV-2 infection in immunocompromised patients. Curr Opin Infect Dis 37(6):506\u2013517. https:\/\/doi.org\/10.1097\/QCO.0000000000001070","journal-title":"Curr Opin Infect Dis"},{"issue":"8","key":"5623_CR11","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.cmi.2024.04.009","volume":"30","author":"SE Meijer","year":"2024","unstructured":"Meijer SE, Paran Y, Belkin A, Ben-Ami R, Maor Y, Nesher L, Hussein K, Rahav G, Brosh-Nissimov T, Persistent (2024) COVID-19 in immunocompromised patients-Israeli society of infectious diseases consensus statement on diagnosis and management. Clin Microbiol Infect 30(8):1012\u20131017 Epub 2024 Apr 18. PMID: 38642895","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"5623_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12985-023-02269-8","volume":"20","author":"I Gentile","year":"2023","unstructured":"Gentile I, Foggia M, Silvitelli M, Sardanelli A, Cattaneo L, Viceconte G (2023) Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir\/ritonavir and sotrovimab. Virol J 20(1):301. https:\/\/doi.org\/10.1186\/s12985-023-02269-8 PMID: 38102675; PMCID: PMC10724917","journal-title":"Virol J"},{"key":"5623_CR13","doi-asserted-by":"publisher","unstructured":"Mikulska M, Sepulcri C, Dentone C, Magne F, Balletto E, Baldi F, Labate L, Russo C, Mirabella M, Magnasco L, Di Grazia C, Ghiggi C, Raiola AM, Giacobbe DR, Vena A, Beltramini S, Bruzzone B, Lemoli RM, Angelucci E, Bassetti M (2023) Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis.77(2):280\u2013286. https:\/\/doi.org\/10.1093\/cid\/ciad181","DOI":"10.1093\/cid\/ciad181"},{"issue":"1","key":"5623_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jmii.2023.09.004","volume":"57","author":"T Brosh-Nissimov","year":"2024","unstructured":"Brosh-Nissimov T, Ma\u2019aravi N, Leshin-Carmel D, Edel Y, Ben Barouch S, Segman Y, Cahan A, Barenboim E (2024) Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir\/ritonavir and tixegavimab\/cilgavimab. J Microbiol Immunol Infect 57(1):189\u2013194. https:\/\/doi.org\/10.1016\/j.jmii.2023.09.004","journal-title":"J Microbiol Immunol Infect"},{"key":"5623_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09466-y","volume":"24","author":"S Rotundo","year":"2024","unstructured":"Rotundo S, Berardelli L, Gull\u00ec S et al (2024) Early initiation of combined therapy in severely immunocompromised patients with COVID-19: a retrospective cohort study. BMC Infect Dis 24:564. https:\/\/doi.org\/10.1186\/s12879-024-09466-y","journal-title":"BMC Infect Dis"},{"key":"5623_CR16","doi-asserted-by":"publisher","unstructured":"Bavaro DF, Diella L, Belati A, Metrangolo G, De Santis L, Spada V, Camporeale M, Dargenio A, Brindicci G, Balena F, Fiordelisi D, Signorile F, Loseto G, Pasciolla C, Minoia C, Attolico I, Perrone T, Simone S, Rendina M, Giovine N, Di Gennaro F, Musto P, Guarini A, Di Leo A, Gesualdo L, Dell\u2019Aera M, Saracino A (2023) Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study. Viruses 15(5):1199. https:\/\/doi.org\/10.3390\/v15051199","DOI":"10.3390\/v15051199"},{"key":"5623_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105894","volume":"227","author":"R Ameratunga","year":"2024","unstructured":"Ameratunga R, Jordan A, Lehnert K, Leung E, Mears ER, Snell R, Steele R, Woon ST (2024) SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: is there a future therapeutic role for soluble ACE2 receptors for COVID-19? Antiviral Res 227:105894. https:\/\/doi.org\/10.1016\/j.antiviral.2024.105894","journal-title":"Antiviral Res"},{"issue":"10","key":"5623_CR18","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S2213-2600(22)00215-6","volume":"10","author":"ACTIV-3\u2013Therapeutics for Inpatients with COVID-19 (TICO) Study Group","year":"2022","unstructured":"ACTIV-3\u2013Therapeutics for Inpatients with COVID-19 (TICO) Study Group (2022) Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med 10(10):972\u2013984. https:\/\/doi.org\/10.1016\/S2213-2600(22)00215-6","journal-title":"Lancet Respir Med"},{"key":"5623_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-087179","volume":"390","author":"AG Cashin","year":"2025","unstructured":"Cashin AG, Hansford HJ, Hern\u00e1n MA, Swanson SA, Lee H, Jones MD, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X, Golub RM, Islam N, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sharp MK, Sterne JAC, Stuart EA, McAuley JH (2025) Transparent reporting of observational studies emulating a target trial: the TARGET statement. BMJ 390:e087179. https:\/\/doi.org\/10.1136\/bmj-2025-087179","journal-title":"BMJ"},{"issue":"9","key":"5623_CR20","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.cmi.2025.04.027","volume":"31","author":"O Martinuka","year":"2025","unstructured":"Martinuka O, le Cessie S, Wolkewitz M (2025) Target trial emulation framework: mitigating methodological challenges and application in COVID-19 treatment evaluation studies. Clin Microbiol Infect 31(9):1475\u20131483. https:\/\/doi.org\/10.1016\/j.cmi.2025.04.027","journal-title":"Clin Microbiol Infect"},{"key":"5623_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70223","author":"M Webster-Clark","year":"2025","unstructured":"Webster-Clark M, Li Y, Dell\u2019Aniello S, Platt RW (2025) Demystifying Clone-Censor-Weighting to Studying Treatment Initiation Windows: An Example Using Publicly Available Synthetic Medicare Claims Data. Pharmacoepidemiol Drug Saf 34(10):e70223. https:\/\/doi.org\/10.1002\/pds.70223"},{"issue":"7","key":"5623_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kwq439","volume":"173","author":"MJ Funk","year":"2011","unstructured":"Funk MJ, Westreich D, Wiesen C, St\u00fcrmer T, Brookhart MA, Davidian M (2011) Doubly robust estimation of causal effects. Am J Epidemiol 173(7):761\u20137. https:\/\/doi.org\/10.1093\/aje\/kwq439","journal-title":"Am J Epidemiol"},{"issue":"11","key":"5623_CR23","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s40121-025-01231-1","volume":"14","author":"C Sepulcri","year":"2025","unstructured":"Sepulcri C, Bartalucci C, Balletto E, Dentone C, Magn\u00e9 F, Mirabella M, Dettori S, Bavastro M, Di Grazia C, Raiola AM, Gambella M, Ricucci V, Bruzzone B, Beltramini S, Angelucci E, Bassetti M, Mikulska M (2025) Antiviral combination treatment for COVID-19 in immunocompromised patients: towards defining its place in therapy. Infect Dis Ther 14(11):2521\u20132533. https:\/\/doi.org\/10.1007\/s40121-025-01231-1","journal-title":"Infect Dis Ther"},{"key":"5623_CR24","doi-asserted-by":"publisher","unstructured":"Pinargote-Celorio H, Moreno-P\u00e9rez \u00d3, Gonz\u00e1lez-De-La-Aleja P, Llenas-Garc\u00eda J, Mart\u00ednez P\u00e9rez-Crespo PM, Rodr\u00edguez-D\u00edaz JC, Mart\u00ednez-L\u00f3pez B, Merchante Guti\u00e9rrez N, Ramos-Rinc\u00f3n JM, Merino E (2024) Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score-adjusted retrospective cohort study. J Antimicrob Chemother. 79(12):3248\u20133253. https:\/\/doi.org\/10.1093\/jac\/dkae351.","DOI":"10.1093\/jac\/dkae351"},{"issue":"Supplement4","key":"5623_CR25","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1093\/cid\/ciae510","volume":"79","author":"E Mozaffari","year":"2024","unstructured":"Mozaffari E, Chandak A, Gottlieb RL, Chima-Melton C, Berry M, Amin AN, Sax PE, Kalil AC (2024) Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era. Clin Infect Dis 79(Supplement4):S149\u2013S159. https:\/\/doi.org\/10.1093\/cid\/ciae510 PMID: 39405443; PMCID: PMC11638779","journal-title":"Clin Infect Dis"},{"issue":"2","key":"5623_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jaci.2021.10.031","volume":"149","author":"LK Brown","year":"2022","unstructured":"Brown LK, Moran E, Goodman A, Baxendale H, Bermingham W, Buckland M, AbdulKhaliq I, Jarvis H, Hunter M, Karanam S, Patel A, Jenkins M, Robbins A, Khan S, Simpson T, Jolles S, Underwood J, Savic S, Richter A, Shields A, Brown M, Lowe DM (2022) Treatment of chronic or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol 149(2):557-561.e1. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.031","journal-title":"J Allergy Clin Immunol"},{"key":"5623_CR27","doi-asserted-by":"publisher","first-page":"100210","DOI":"10.1016\/j.clinpr.2022.100210","volume":"16","author":"D Hettle","year":"2022","unstructured":"Hettle D, Hutchings S, Muir P, Moran E, COVID-19 Genomics UK (COG-UK) consortium (2022) Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review. Clin Infect Pract 16:100210. https:\/\/doi.org\/10.1016\/j.clinpr.2022.100210Epub 2022 Nov 16. PMID: 36405361; PMCID: PMC9666269","journal-title":"Clin Infect Pract"},{"issue":"3","key":"5623_CR28","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/S2666-5247(23)00336-1","volume":"5","author":"Z Raglow","year":"2024","unstructured":"Raglow Z, Surie D, Chappell JD, Zhu Y, Martin ET, Kwon JH, Frosch AE, Mohamed A, Gilbert J, Bendall EE, Bahr A, Halasa N, Talbot HK, Grijalva CG, Baughman A, Womack KN, Johnson C, Swan SA, Koumans E, McMorrow ML, Harcourt JL, Atherton LJ, Burroughs A, Thornburg NJ, Self WH, Lauring AS (2024) Investigating Respiratory Viruses in the Acutely Ill (IVY) Network. SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis. Lancet Microbe 5(3):e235\u2013e246. https:\/\/doi.org\/10.1016\/S2666-5247(23)00336-1 Epub 2024 Jan 26. PMID: 38286131","journal-title":"Lancet Microbe"},{"key":"5623_CR29","doi-asserted-by":"publisher","unstructured":"Hirsch C, Kreuzberger N, Skoetz N, Monsef I, Kluge S, Spinner CD, Malin JJ (2025) Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review. J Antimicrob Chemother. 13:dkae482. https:\/\/doi.org\/10.1093\/jac\/dkae482","DOI":"10.1093\/jac\/dkae482"},{"issue":"2","key":"5623_CR30","doi-asserted-by":"publisher","first-page":"e70215","DOI":"10.1002\/jmv.70215","volume":"97","author":"A Bergna","year":"2025","unstructured":"Bergna A, Lai A, Sagradi F, Menzo S, Mancini N, Bruzzone B, Rusconi S, Marchegiani G, Clementi N, Francisci D, Vicenti I, Ronchiadin S, Mbissam HD, Della Ventura C, Lanfranchi L, Testa S, Caucci S, Acciarri C, Carioti L, Occhionero A, Novazzi F, Genoni AP, Ferrante FD, De Pace V, Ferraris M, Ogliastro M, Gabrieli A, De Paschale M, Canavesi G, Bellocchi MC, Iannetta M, Sarmati L, Ceccherini-Silberstein F, Riva A, Antinori S, Zehender G (2025) SARS-CoV\u20102 ITALIAN RESEARCH ENTERPRISE \u2013 collaborative Group. Genomic Epidemiology of the Main SARS-CoV-2 Variants Circulating in Italy During the Omicron Era. J Med Virol 97(2):e70215. https:\/\/doi.org\/10.1002\/jmv.70215 PMID: 39936851; PMCID: PMC11816846","journal-title":"J Med Virol"},{"issue":"3","key":"5623_CR31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/v16030354","volume":"16","author":"A Ref. Gidari","year":"2024","unstructured":"Ref. Gidari A, Sabbatini S, Bastianelli S, Pierucci S, Busti C, Svizzeretto E, Tommasi A, Pallotto C, Schiaroli E, Francisci D (2024) Tixagevimab\/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants? Viruses 16(3):354. https:\/\/doi.org\/10.3390\/v16030354 PMID: 38543720; PMCID: PMC10975286","journal-title":"Viruses"},{"issue":"10","key":"5623_CR32","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.medj.2023.07.007","volume":"4","author":"T Bruel","year":"2023","unstructured":"Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Bolland WH, Souli\u00e9 C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, P\u00e9r\u00e9 H, Yordanov Y, Simon-Lori\u00e8re E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G (2023) ANRS 0003S CoCoPrev Study Group. Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients. Med 4(10):664\u2013667. https:\/\/doi.org\/10.1016\/j.medj.2023.07.007 PMID: 37837962; PMCID: PMC11232389","journal-title":"Med"},{"issue":"6","key":"5623_CR33","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1093\/cid\/ciae026","volume":"78","author":"S Huygens","year":"2024","unstructured":"Huygens S, GeurtsvanKessel C, Gharbharan A, Bogers S, Worp N, Boter M, Bax HI, Kampschreur LM, Hassing RJ, Fiets RB, Levenga H, Afonso PM, Koopmans M, Rijnders BJA, Oude Munnink BB (2024) Clinical and virological outcome of monoclonal antibody therapies across SARS-CoV-2 variants in 245 immunocompromised patients: a multicenter prospective cohort study. Clin Infect Dis 78(6):1514\u20131521. https:\/\/doi.org\/10.1093\/cid\/ciae026","journal-title":"Clin Infect Dis"},{"issue":"3","key":"5623_CR34","doi-asserted-by":"publisher","first-page":"e176359","DOI":"10.1172\/jci.insight.176359","volume":"9","author":"O Zimmerman","year":"2024","unstructured":"Zimmerman O, Altman Doss AM, Ying B, Liang CY, Mackin SR, Davis-Adams HG, Adams LJ, VanBlargan LA, Chen RE, Scheaffer SM, Desai P, Raju S, Mantia TL, O\u2019Shaughnessy CC, Monroy JM, Wedner HJ, Rigell CJ, Kau AL, Dy TB, Ren Z, Turner JS, O\u2019Halloran JA, Presti RM, Kendall PL, Fremont DH, Ellebedy AH, Diamond MS (2024) Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity. JCI Insight 9(3):e176359. https:\/\/doi.org\/10.1172\/jci.insight.176359 PMID: 38175703; PMCID: PMC10967375","journal-title":"JCI Insight"},{"issue":"11","key":"5623_CR35","doi-asserted-by":"publisher","first-page":"e0259731","DOI":"10.1371\/journal.pone.0259731","volume":"16","author":"S Stinca","year":"2021","unstructured":"Stinca S, Barnes TW, Vogel P, Meyers W, Schulte-Pelkum J, Filchtinski D, Steller L, Hauser T, Manni S, Gardiner DF, Popik S, Roth NJ, Schuetz P (2021) Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches. PLoS ONE 16(11):e0259731. https:\/\/doi.org\/10.1371\/journal.pone.0259731 PMID: 34843493; PMCID: PMC8629175","journal-title":"PLoS ONE"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05623-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05623-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05623-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:35:59Z","timestamp":1786606559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05623-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":35,"alternative-id":["5623"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05623-0","relation":{"references":[{"id-type":"doi","id":"10.1002\/pds.70223","asserted-by":"subject"}]},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review board approved the study of the coordinating center (Comitato Etico Policlinico di Bari, pratica N.7583) and was in accordance with the declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patients provided a written informed consent (available from the corresponding author) for the use of their data for research purposes.","order":2,"name":"Ethics","label":"Patient consent statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The lead author affirms that this manuscript is an honest, accurate and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any discrepancies from the study as planned have been explained. The manuscript was written by the lead\/corresponding author and that authors have no financial conflicts of interest to declare related to this work.","order":3,"name":"Ethics","label":"Transparency declaration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}